Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 3, 2004. The report details a share repurchase transaction executed on September 2, 2004, and updates regarding directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,137.71 pence per share.
- Treasury Holdings: 40,818,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,893,499,051 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 750,000 shares. Additionally, the GlaxoSmithKline US Retirement Savings Plan reported a decrease in its holdings of Ordinary Share ADRs from 19,223,894 to 19,172,434 due to fund movements on September 2, 2004, at an average price of $41.31.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 750,000 share repurchase based on the disclosed price of 1,137.71 pence per share.
- Confirm the updated total share count of 5,893,499,051 shares in issue.
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have potential indirect interests in the US Retirement Savings Plan, which saw a reduction in ADR holdings.
- Recognize that this filing does not contain quarterly or annual financial performance data.